Navigation Links
Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth
Date:10/15/2008

CLEVELAND, Ohio and TEL AVIV, Israel, October 15 /PRNewswire/ -- Simbionix USA Corporation is pleased to announce the completion of a Series C round of growth capital financing led by River Cities Capital Funds, along with incumbent investor Early Stage Partners and other existing shareholders, as well as Western Reserve Partners who served as the company's investment bankers. The investment will enable Simbionix to accelerate the already rapid growth of its medical simulation technology via the introduction of innovative new products and expanded distribution channels. "This significant funding will help us continue the company's momentum and support Simbionix's commitment to maintain its position as the global leader in medical simulation technology," stated Dr. Avshalom Horan, Chairman.

"We are excited about the market's validation of our technology as well as the strong financial support of River Cities and the continuing support of our existing investors," commented Gary Zamler Simbionix CEO. "This infusion of new growth capital will fuel further domestic and international growth of our existing products as well as our emerging products - that includes the recently launched PROcedure Rehearsal Studio, a truly revolutionary virtual reality endovascular simulator with unprecedented hands-on, "patient-specific training capabilities," he added. "Simbionix works closely with global leaders in healthcare, both on the medical device side and the provider side. They take comfort with Simbionix as a partner because of our size, profitability, and the resources to bring innovative products to market," Mr. Zamler concluded.

Ran Bronstein, Simbionix President and one of its founders commented "funding of this sort is an important achievement for the Simbionix team. It's an additional indication demonstrating the growth and the validity of the medical education and simulation market since River Cities has experience in both fields. We welcome River Citi
'/>"/>

SOURCE Simbionix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
2. Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level
3. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
4. Simbionix Launches Innovative Patient-Specific Simulation
5. Pearl Therapeutics Raises $15.5 Million in Private Financing
6. Enobia Pharma Raises $40.1 Million Series B Financing
7. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
8. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
9. VisEn Medical Raises $7 Million in Series B Financing
10. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
11. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... United Therapeutics Corporation (Nasdaq: ... its fourth quarter and annual 2009 financial results ... 2010 . ,, United Therapeutics will host a ... , at 9:00 a.m. Eastern Time . ... international callers dialing 1-719-325-2204.  A rebroadcast of the ...
(Date:2/9/2010)... ,, ... Improve the Treatment,of a Range of Back of ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company,focused ... for eye,disease, vascular disease and cancer, announces today ... the product,s efficacy and,safety in patients who require ...
(Date:2/8/2010)... from NASA’s Kennedy Space Center this morning, carrying on board ... created to use microgravity to develop the foundation of new ... ... 2010 -- Space Shuttle Endeavor lifted off from NASA’s Kennedy ... payload for Astrogenetix, a commercial biotech company created to use ...
(Date:2/8/2010)... ORLEANS , Feb. 8 Corgenix ... and marketer of diagnostic test kits, and Tulane ... collaborative effort to combat viral hemorrhagic fever (VHF), an ... in contract revenue for Corgenix over the life of ... (NIH) has awarded a five-year contract totaling $15,224,927 ...
Breaking Biology Technology:ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 2Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7
... VAUDREUIL-DORION, QC, Oct. 11 /PRNewswire-FirstCall/ - The Board ... announce the appointment of,Mr. James A. Northrop as ... A member of the Board of Directors ... executive with a record of success in rapid ...
... Access Genetics, an Eden Prairie-,based molecular diagnostics service and ... Hoedeman as its CFO, and Elizabeth A. Skinner,as VP ... recently CFO of Edwin Watts Golf, and has previously,served ... CIO of Allied Signal,Aerospace, and corporate controller of NCR ...
... and CAPE TOWN, South Africa, Oct. 11, Iomai Corporation ... Officer Gregory Glenn, M.D., presented an,overview of the clinical ... implications such a vaccine could have on,global health at ... in Cape Town, South Africa. Last month, Dr. ...
Other Biology Technology:Immunotec Inc. announces appointment of President & CEO James A. Northrop 2Access Genetics Announces New Executive Appointments 2Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 2Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 3Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 4
(Date:2/8/2010)... ST. PAUL, Minn. A Mediterranean diet may help ... can lead to problems with thinking and memory, according ... at the American Academy of Neurology,s 62nd Annual Meeting ... The study found that people who ate a ... or small areas of dead tissue linked to thinking ...
(Date:2/8/2010)... PROVIDENCE, R.I. [Brown University] Around 30 to 40 ... evolutionary upheaval. An assemblage capitalized on falling levels of ... concentrate the dwindling CO2 supply that, like a fuel-injection ... and nutrients into energy. , The rise of C4 ... climes and now make up to 20 percent of ...
(Date:2/8/2010)... 8 The nation,s first fully ... to simultaneously improve health and reduce healthcare spending ... www.thefullyield.com .  The Full Yield rolls out ... an initially exclusive partnership with Harvard Pilgrim ... plan in the U.S., and an inaugural partnership ...
Breaking Biology News(10 mins):Mediterranean diet may lower risk of brain damage that causes thinking problems 2Brown biologist solves mystery of tropical grasses' origin 2Brown biologist solves mystery of tropical grasses' origin 3The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 2The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 3The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 4The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare 5New information about how fat increases blood pressure could help identify those at risk 9752 1New information about how fat increases blood pressure could help identify those at risk 9752 2New information about how fat increases blood pressure could help identify those at risk 9752 3Over time an invasive plant loses its toxic edge 9749 1Over time an invasive plant loses its toxic edge 9749 2Over time an invasive plant loses its toxic edge 9749 3Video 3A Project Runway Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 55866 1Video 3A Project Runway Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 55866 2Video 3A Project Runway Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma 55866 3
... organic farming becomes more common, methods to identify ... a recent study in Journal of Environmental Quality, ... if non-organic, synthetic fertilizers were used on sweet ... de Investigacin y Desarrollo Agrario y Agrario y ...
... University of Miamis Rosenstiel School of Marine and ... Dennis J. McGillicuddy, Jr., Ph.D., as recipient of ... in the department of Applied Ocean Physics and ... in Woods Hole, Mass., is a pioneer in ...
... an innovative computational approach could speed up the process ... researchers from the University of Chicago Medical Center and ... in the February 2008 issue of Genome Research, available ... the human genes and proteins that serve as targets ...
Other Biology News:Is it organic or not? 2Oceanographer Dennis J. McGillicuddy, Jr. receives 34th annual Rosenstiel Award 2Study of successful drug targets could hasten development of new medications 2Study of successful drug targets could hasten development of new medications 3